TerrAscend Earnings Reports — Quarterly Financial Performance & Analysis

Executive Summary

TerrAscend Corp., a vertically integrated multi-state operator trading under ticker symbol TSND (CSE) and TRSSF (OTCQX), has established itself as a consistent financial performer in the North American cannabis industry through disciplined earnings reporting and strategic market positioning. The company operates cultivation, processing, and retail facilities across Pennsylvania, New Jersey, Maryland, Michigan, and California, generating quarterly revenues that have positioned it among the top-tier cannabis operators by market capitalization. TerrAscend's earnings reports serve as key indicators for institutional investors evaluating the cannabis sector's maturation, with the company's financial disclosures providing transparency into wholesale pricing dynamics, retail foot traffic trends, and the operational efficiency of vertically integrated cannabis businesses. As of May 2026, TerrAscend continues to report solid quarterly revenue figures while navigating federal rescheduling discussions, state-level regulatory changes, and evolving capital market conditions that affect publicly traded cannabis companies.

Why TerrAscend Earnings Matter

TerrAscend's quarterly financial disclosures influence investment decisions affecting billions in cannabis sector capital allocation and provide operational benchmarks for approximately 150 licensed operators across five state markets. The company's earnings reports matter to multiple stakeholder groups with distinct interests in the data. Institutional investors and equity analysts use TerrAscend's revenue figures, EBITDA margins, and same-store sales growth to model valuation multiples for the broader multi-state operator sector. When TerrAscend reports gross margins above 50 percent or adjusted EBITDA margins exceeding 25 percent, these figures establish performance thresholds that competitors must meet to maintain investor confidence. The company's market capitalization has fluctuated between $400 million and $1.2 billion since 2021, making it a significant component of cannabis-focused ETFs and institutional portfolios. Medical cannabis patients in Pennsylvania and New Jersey—states where TerrAscend operates approximately 20 retail dispensaries—experience direct impacts from the company's inventory management and pricing strategies revealed in earnings calls. When TerrAscend reports inventory turnover rates or discusses promotional pricing to clear aged flower inventory, these operational decisions translate to product availability and pricing at the dispensary counter. State regulatory agencies in Pennsylvania, New Jersey, Maryland, Michigan, and California monitor TerrAscend's financial health as an indicator of license holder stability and tax revenue generation. The company's reported state excise tax payments and local tax contributions provide revenue streams that fund regulatory oversight, social equity programs, and municipal services in jurisdictions where TerrAscend operates cultivation and retail facilities. Competitors including Curaleaf, Green Thumb Industries, Trulieve, Verano, and Cresco Labs benchmark their own performance against TerrAscend's disclosed metrics. When TerrAscend reports revenue per square foot of cultivation space or cost per gram of production, these figures become industry standards that inform capacity expansion decisions and operational efficiency initiatives across the sector.

Background and History: TerrAscend's Evolution as a Public Cannabis Company

TerrAscend's journey from a Canadian cannabis investment vehicle to a U.S.-focused multi-state operator spans nearly a decade of strategic pivots, capital raises, and market consolidation that shaped its current earnings profile.

2017-2018: Formation and Initial Public Listing

TerrAscend Corporation formed in 2017 as a Canadian-domiciled entity designed to capitalize on cannabis legalization trends in North America. The company completed its initial public offering on the Canadian Securities Exchange in March 2018, raising approximately $35 million CAD at a time when Canadian cannabis stocks were experiencing a speculative boom ahead of federal legalization in Canada. Unlike pure-play Canadian licensed producers, TerrAscend structured itself from inception to pursue U.S. state-legal cannabis opportunities through subsidiaries that maintained operational separation from the Canadian parent company to comply with CSE listing requirements. The company's early strategy focused on securing cultivation and processing licenses in limited-license states where regulatory barriers to entry would theoretically protect market share and pricing power. TerrAscend acquired its first significant U.S. asset in 2018 when it purchased a cultivation and processing license in Pennsylvania for approximately $8 million, establishing a foothold in a medical-only market that would later become its largest revenue contributor.

2019: The Ilera Healthcare Acquisition

In January 2019, TerrAscend completed its acquisition of Ilera Healthcare, a Pennsylvania-based grower-processor with operational cultivation facilities and an established wholesale distribution network serving the state's then-nascent medical marijuana program. The $67 million transaction marked TerrAscend's transition from a license-holding shell company to an operating business generating measurable revenue. Ilera's existing cultivation capacity in Pennsylvania provided immediate cash flow that would fund subsequent expansion. The company reported its first material quarterly revenue of $8.2 million in Q2 2019, derived primarily from wholesale sales of flower and vape cartridges to Pennsylvania dispensaries operated by third parties. This wholesale-focused model would later shift toward vertical integration as TerrAscend opened its own retail locations.

2020: New Jersey Expansion and The Apothecarium Acquisition

TerrAscend entered the New Jersey medical cannabis market in early 2020 through its acquisition of a cultivation and retail license, opening a dispensary in Maplewood that would later become one of the highest-grossing cannabis retail locations on the East Coast following adult-use legalization. The company invested approximately $25 million in cultivation infrastructure in New Jersey during 2020, building out a 100,000-square-foot indoor grow facility designed to supply both its own retail stores and the wholesale market. In November 2020, TerrAscend acquired The Apothecarium, a California-based cannabis retailer operating dispensaries in San Francisco and other Bay Area locations, for $120 million in stock and cash. The transaction added premium retail assets in a mature market and brought experienced retail management to TerrAscend's executive team. The Apothecarium brand became TerrAscend's primary retail banner in California, though the company would later face margin pressure in that highly competitive market. By Q4 2020, TerrAscend reported quarterly revenue of $48 million, representing year-over-year growth of approximately 170 percent. The company's earnings reports began attracting attention from institutional investors seeking exposure to U.S. cannabis growth.

2021: Profitability and Capital Markets Access

TerrAscend achieved its first profitable quarter on a net income basis in Q1 2021, reporting net income of $4.3 million on revenue of $58 million. This milestone distinguished TerrAscend from many multi-state operator peers that continued to report net losses due to aggressive expansion spending and the impact of Internal Revenue Code Section 280E, which disallows federal tax deductions for businesses trafficking in Schedule I controlled substances. The company completed a $115 million registered direct offering in March 2021, selling shares to institutional investors at $11.50 per share. This capital raise funded the construction of additional cultivation capacity in New Jersey and Pennsylvania, positioning TerrAscend to capture demand from adult-use legalization in New Jersey, which voters approved in November 2020 but which would not launch until April 2022. TerrAscend's Q3 2021 earnings report disclosed revenue of $67 million and adjusted EBITDA of $21 million, representing an adjusted EBITDA margin of 31 percent—among the highest in the multi-state operator sector at that time. The company's management attributed the strong margins to vertical integration in Pennsylvania and New Jersey, where TerrAscend supplied its own retail stores with house-branded products that carried higher margins than third-party wholesale.

2022: New Jersey Adult-Use Launch and Market Volatility

New Jersey commenced adult-use cannabis sales on April 21, 2022, and TerrAscend's retail locations in Maplewood and Lodi immediately became among the state's highest-volume dispensaries. The company reported Q2 2022 revenue of $72 million, with New Jersey contributing approximately 35 percent of total revenue—a significant increase from the prior year when New Jersey represented less than 20 percent of revenue. However, 2022 also brought significant headwinds. Cannabis equity valuations collapsed as rising interest rates and macroeconomic uncertainty drove investors away from growth stocks. TerrAscend's share price declined from a high of approximately $8.00 USD in early 2022 to below $2.00 USD by year-end. The company's market capitalization fell below $500 million despite continued revenue growth. TerrAscend's Q4 2022 earnings report disclosed revenue of $70 million, representing a sequential decline from Q3 2022 revenue of $73 million. Management attributed the decline to wholesale pricing pressure in Pennsylvania and Michigan, where increased cultivation capacity from competitors drove down per-gram wholesale prices by approximately 20 percent year-over-year.

2023-2024: Operational Efficiency and Margin Defense

Facing a challenging capital markets environment with limited access to equity financing at acceptable valuations, TerrAscend shifted strategic focus toward operational efficiency and free cash flow generation. The company's 2023 earnings reports emphasized cost reduction initiatives, including workforce optimization that reduced headcount by approximately 10 percent and the closure of underperforming retail locations in California. TerrAscend reported full-year 2023 revenue of $286 million, representing modest growth of 4 percent compared to 2022. However, the company maintained adjusted EBITDA margins above 28 percent throughout 2023, demonstrating pricing power and operational discipline in a maturing market. In 2024, TerrAscend's earnings reports began highlighting the company's focus on branded product development, particularly in the vape cartridge and infused pre-roll categories. The company's house brands, including Gage Cannabis Co. in Michigan and Kind Tree in New Jersey and Pennsylvania, gained market share in their respective states. Q3 2024 earnings disclosed that branded products represented 62 percent of TerrAscend's retail revenue, up from 48 percent in Q3 2023.

2025-2026: Federal Rescheduling Anticipation

TerrAscend's earnings reports in 2025 and early 2026 occurred against the backdrop of the Drug Enforcement Administration's proposed rulemaking to reschedule cannabis from Schedule I to Schedule III of the Controlled Substances Act under 21 U.S.C. § 812. While rescheduling would not legalize cannabis under federal law, it would eliminate the application of 280E to cannabis businesses, potentially increasing TerrAscend's net income by 30 to 40 percent by allowing normal business expense deductions. The company's Q1 2026 earnings call in March 2026 included management commentary on the potential financial impact of rescheduling, with CFO Keith Stauffer stating that TerrAscend currently pays an effective tax rate of approximately 70 percent due to 280E limitations, compared to a normalized corporate tax rate of approximately 25 percent that would apply if cannabis were rescheduled. As of May 2026, TerrAscend's most recent earnings report disclosed quarterly revenue that analysts characterized as "solid," continuing the company's track record of consistent financial performance while the broader cannabis sector awaits regulatory clarity on federal scheduling.

Key Players in TerrAscend's Earnings Narrative

TerrAscend's financial performance and earnings disclosures involve a network of executives, investors, regulators, and market analysts whose actions and statements shape market interpretation of the company's results.

Jason Wild: Executive Chairman and Largest Shareholder

Jason Wild serves as Executive Chairman of TerrAscend and controls approximately 23 percent of the company's outstanding shares through his investment vehicle JW Asset Management. Wild, a former pharmaceutical industry executive, has been involved with TerrAscend since its formation and has provided strategic direction for the company's focus on limited-license states and vertical integration. Wild's significant ownership stake aligns his interests with public shareholders, and his commentary on earnings calls carries weight with institutional investors. Wild has consistently emphasized disciplined capital allocation and organic growth over acquisitive expansion in his public statements.

Ziad Ghanem: President and Chief Operating Officer

Ziad Ghanem joined TerrAscend in 2019 and oversees the company's cultivation, processing, and retail operations across all five states. Ghanem's operational background includes prior roles in consumer packaged goods and retail, and he has implemented standardized operating procedures across TerrAscend's facilities that contribute to the company's consistent margins. Ghanem typically presents operational metrics on earnings calls, including same-store sales growth, inventory turnover, and production costs per gram.

Keith Stauffer: Chief Financial Officer

Keith Stauffer has served as TerrAscend's CFO since 2020 and manages the company's financial reporting, capital structure, and investor relations. Stauffer's earnings call presentations focus on GAAP revenue, adjusted EBITDA reconciliations, and cash flow generation. His commentary on working capital management and capital expenditure priorities provides insight into TerrAscend's near-term liquidity and growth investment plans.

Institutional Investors: ETFs and Long-Only Funds

TerrAscend's shareholder base includes several cannabis-focused ETFs, including the AdvisorShares Pure U.S. Cannabis ETF (MSOS) and the Amplify Seymour Cannabis ETF (CNBS), which collectively hold approximately 8 percent of outstanding shares. These passive investment vehicles create a stable shareholder base but also mean that TerrAscend's stock price is influenced by sector-wide sentiment rather than company-specific fundamentals. Long-only institutional investors including Wasatch Advisors and Perkins Investment Management hold significant positions and engage with management on capital allocation and governance matters.

Equity Analysts: Canaccord Genuity, Stifel, and Alliance Global Partners

Several investment banks provide equity research coverage of TerrAscend, publishing earnings previews and post-earnings analysis that influence investor perception. Canaccord Genuity analyst Matt Bottomley has covered TerrAscend since 2019 and typically models the company's earnings based on state-level market share assumptions and pricing trends. Stifel analyst Andrew Carter focuses on TerrAscend's free cash flow generation and balance sheet strength. These analysts' price targets and rating changes often move TerrAscend's stock price more than the earnings results themselves.

State Regulators: Pennsylvania, New Jersey, and Michigan

The Pennsylvania Department of Health's Medical Marijuana Program, the New Jersey Cannabis Regulatory Commission, and the Michigan Cannabis Regulatory Agency all oversee TerrAscend's licensed operations in their respective states. These agencies review TerrAscend's financial disclosures as part of ongoing license compliance monitoring. Regulatory actions such as license renewals, inspection findings, or enforcement actions can materially impact TerrAscend's earnings by affecting operational continuity or requiring remediation spending.

Legal and Regulatory Framework Affecting TerrAscend's Financial Reporting

TerrAscend's earnings reports operate within a complex legal framework spanning Canadian securities law, U.S. state cannabis regulations, and federal tax and banking restrictions that create unique financial reporting challenges. TerrAscend files its financial statements under Canadian securities regulations as a reporting issuer on the Canadian Securities Exchange. The company prepares its financial statements in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board, rather than U.S. Generally Accepted Accounting Principles (GAAP). This creates comparability challenges for U.S. investors more familiar with GAAP reporting, particularly in areas such as biological asset accounting for cannabis inventory. Under IFRS, TerrAscend must fair-value its biological assets—cannabis plants in various stages of growth—at each reporting period, with changes in fair value recognized in the income statement. This accounting treatment creates earnings volatility unrelated to cash sales, as the estimated fair value of growing plants fluctuates based on expected yields and wholesale pricing assumptions. TerrAscend's earnings reports include detailed reconciliations showing the impact of biological asset fair value changes on reported revenue and gross profit. Internal Revenue Code Section 280E prohibits businesses trafficking in Schedule I or Schedule II controlled substances from deducting ordinary business expenses for federal tax purposes, with the exception of cost of goods sold. Because cannabis remains a Schedule I controlled substance under the Controlled Substances Act (21 U.S.C. § 812), TerrAscend cannot deduct operating expenses such as rent, marketing, salaries for non-production employees, or interest expense when calculating federal taxable income. This results in effective tax rates exceeding 70 percent of pre-tax income, dramatically reducing net income reported in TerrAscend's earnings. The company's earnings reports include detailed disclosures of the 280E impact, typically presented as a reconciliation between adjusted EBITDA (which excludes taxes) and net income. If the DEA's proposed rescheduling to Schedule III is finalized, 280E would no longer apply to cannabis businesses, and TerrAscend's net income would increase substantially even with no change in operational performance. TerrAscend's access to banking services affects its financial reporting and cash management. Although the company maintains bank accounts and credit facilities with Canadian financial institutions, its U.S. subsidiaries face limited banking access due to federal prohibition. This requires cash-intensive operations at retail locations and creates working capital inefficiencies. The company's earnings reports disclose cash and cash equivalents, but a portion of this cash is held in non-interest-bearing accounts or as physical currency in safes at dispensary locations. State-level regulations in Pennsylvania, New Jersey, Maryland, Michigan, and California impose varying financial reporting requirements on licensed operators. New Jersey's Cannabis Regulatory Commission requires quarterly financial reports from all licensed businesses, including detailed revenue breakdowns by product category and customer type (medical versus adult-use). These state-level reports must reconcile to TerrAscend's consolidated financial statements, and discrepancies can trigger regulatory inquiries.

State-by-State Breakdown of TerrAscend's Operations

TerrAscend's earnings are generated across five distinct state markets, each with unique regulatory structures, competitive dynamics, and growth trajectories that contribute differently to consolidated financial results.

Pennsylvania: Largest Revenue Contributor

Pennsylvania represents TerrAscend's largest state market by revenue, contributing approximately 40 percent of consolidated revenue as of recent earnings reports. The state operates a medical-only cannabis program established under the Medical Marijuana Act (35 P.S. § 10231.101 et seq.), which does not permit adult-use sales. Pennsylvania issues a limited number of grower-processor permits and dispensary permits, creating a supply-constrained market with relatively stable wholesale and retail pricing. TerrAscend operates cultivation and processing facilities in Avondale and Hazleton, Pennsylvania, with combined annual production capacity exceeding 25,000 kilograms of dried flower equivalent. The company operates approximately eight retail dispensaries in Pennsylvania under the Apothecarium and Keystone Shops banners, located in Philadelphia, Pittsburgh, and suburban markets. Pennsylvania's medical marijuana program serves approximately 450,000 registered patients as of 2026, with qualifying conditions including chronic pain, anxiety disorders, and PTSD. The state imposes no excise tax on medical cannabis sales, though standard sales tax applies. TerrAscend's Pennsylvania operations benefit from vertical integration, with approximately 70 percent of the company's Pennsylvania retail sales consisting of house-branded products manufactured in its own facilities.

New Jersey: Highest-Growth Market

New Jersey became TerrAscend's highest-growth market following the launch of adult-use sales in April 2022. The state's Cannabis Regulatory Commission oversees both medical and adult-use markets under the New Jersey Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act (N.J.S.A. 24:6I-31 et seq.). New Jersey imposes a state excise tax on cannabis sales, with rates varying by product type and THC content. TerrAscend operates cultivation facilities in Boonton, New Jersey, and retail dispensaries in Maplewood, Lodi, and Phillipsburg. The Maplewood location consistently ranks among New Jersey's highest-volume dispensaries, with estimated annual revenue exceeding $30 million. TerrAscend's New Jersey operations contributed approximately 35 percent of consolidated revenue in recent quarters, with strong same-store sales growth driven by adult-use customer acquisition. New Jersey's cannabis market faces increasing competition as the state has issued hundreds of new licenses since 2022, including conditional licenses for social equity applicants. This expanding supply has begun to pressure wholesale pricing, though retail demand remains strong. TerrAscend's earnings calls have noted that New Jersey wholesale flower prices declined approximately 15 percent in 2025 compared to 2024, though the company's vertical integration insulates it from wholesale market volatility.

Michigan: Competitive Wholesale Market

Michigan operates an adult-use cannabis market under the Michigan Regulation and Taxation of Marihuana Act (MCL 333.27951 et seq.), which permits unlimited license issuance subject to local municipal approval. This regulatory structure has created one of the most competitive cannabis markets in the United States, with wholesale flower prices falling below $1,000 per pound in some quarters—among the lowest in the nation. TerrAscend entered Michigan through its 2019 acquisition of Gage Cannabis Co., a vertically integrated operator with cultivation, processing, and retail assets. The company operates a cultivation facility in River Rouge, Michigan, and approximately four retail dispensaries in the Detroit metropolitan area. Michigan contributes approximately 15 percent of TerrAscend's consolidated revenue, with lower margins than Pennsylvania or New Jersey due to intense price competition. TerrAscend's Michigan strategy emphasizes branded product differentiation, particularly in the vape cartridge and concentrate categories where the company's Gage brand has achieved recognition among adult-use consumers. The company's earnings reports have indicated that Michigan operations generate positive EBITDA despite low wholesale pricing, reflecting efficient cultivation and processing operations.

Maryland: Emerging Adult-Use Market

Maryland launched adult-use cannabis sales in July 2023 following voter approval of a constitutional amendment in November 2022. The state's cannabis program operates under the Maryland Medical Cannabis Commission's regulatory framework, which converted existing medical licenses to dual medical/adult-use licenses. Maryland imposes a 9 percent excise tax on adult-use cannabis sales. TerrAscend operates a cultivation facility in Hagerstown, Maryland, and retail dispensaries in Takoma Park and other locations. Maryland contributes approximately 8 percent of consolidated revenue, with growth potential as the adult-use market matures. The state's proximity to Washington, D.C., and Virginia creates cross-border demand dynamics, though federal law prohibits interstate cannabis commerce.

California: Mature but Challenging Market

California represents TerrAscend's smallest state market by revenue contribution, accounting for less than 5 percent of consolidated revenue in recent quarters. The state's adult-use market, established under Proposition 64 and the Medicinal and Adult-Use Cannabis Regulation and Safety Act (Cal. Bus. & Prof. Code § 26000 et seq.), is the largest legal cannabis market in the world by total sales volume but also the most competitive. TerrAscend operates retail dispensaries in San Francisco and other Bay Area locations under The Apothecarium brand. The company does not operate cultivation facilities in California, instead sourcing products from third-party suppliers. California's high tax burden—including a 15 percent excise tax and local taxes that can exceed 10 percent—combined with competition from unlicensed operators, has compressed retail margins. TerrAscend's earnings reports have indicated that California operations generate minimal EBITDA, and the company has closed underperforming California locations to improve overall profitability.

Market and Business Implications of TerrAscend's Earnings

TerrAscend's quarterly financial results provide actionable intelligence for multi-state operators, investors, and suppliers seeking to understand cannabis market dynamics and operational best practices. TerrAscend's consistent adjusted EBITDA margins above 25 percent demonstrate that vertically integrated cannabis operators can achieve profitability despite 280E tax burdens and state-level regulatory costs. This margin profile has influenced capital allocation decisions across the sector, with competitors increasing their own vertical integration to capture cultivation and processing margins. When TerrAscend reports gross margins on retail sales of house-branded products exceeding 60 percent, compared to gross margins below 30 percent on third-party wholesale products, these figures quantify the financial benefit of vertical integration. The company's inventory management practices, disclosed in earnings reports and MD&A filings, provide benchmarks for working capital efficiency. TerrAscend typically maintains inventory turnover of approximately 90 to 120 days, balancing the need for product freshness with the desire to avoid stockouts. When the company reports inventory write-downs due to product aging or regulatory compliance issues, these disclosures highlight operational risks that all cannabis operators face. TerrAscend's capital expenditure patterns, disclosed in cash flow statements accompanying earnings releases, indicate the company's growth investment priorities. In recent quarters, TerrAscend has reduced capital spending to approximately 5 to 8 percent of revenue, down from 15 to 20 percent in earlier years when the company was building out cultivation capacity. This shift toward free cash flow generation rather than growth investment reflects the maturing state of TerrAscend's core markets and limited access to external capital. The company's same-store sales growth metrics, typically disclosed on earnings calls, provide insight into underlying demand trends independent of new store openings. When TerrAscend reports same-store sales growth of 5 to 10 percent year-over-year, this indicates healthy market fundamentals. Conversely, flat or negative same-store sales growth signals market saturation or increased competition. TerrAscend's wholesale pricing commentary on earnings calls offers real-time market intelligence for cultivators and processors. When management discusses wholesale flower prices in Pennsylvania declining from $3,500 per pound to $2,800 per pound over a 12-month period, these figures inform supply planning and capacity expansion decisions across the industry.

What Experts and Analysts Say

Equity analysts, industry consultants, and cannabis sector observers interpret TerrAscend's earnings through multiple analytical frameworks that emphasize different aspects of the company's performance. Canaccord Genuity analyst Matt Bottomley has characterized TerrAscend as a "best-in-class operator" in research notes following earnings releases, citing the company's margin discipline and market share gains in Pennsylvania and New Jersey. Bottomley's earnings models typically focus on TerrAscend's ability to maintain EBITDA margins above 25 percent while competitors face margin compression, attributing this performance to vertical integration and brand strength. Stifel analyst Andrew Carter has emphasized TerrAscend's free cash flow generation in post-earnings analysis, noting that the company has reduced its reliance on external capital markets by generating sufficient cash from operations to fund maintenance capital expenditures and working capital needs. According to Carter's published research, TerrAscend's free cash flow yield—free cash flow divided by market capitalization—has been among the highest in the multi-state operator sector, suggesting the stock trades at an attractive valuation relative to cash generation. Viridian Capital Advisors, a cannabis-focused investment bank, has included TerrAscend in its quarterly analysis of multi-state operator financial performance, comparing the company's revenue growth, EBITDA margins, and leverage ratios to sector peers. Viridian's research has noted that TerrAscend maintains a relatively conservative balance sheet with total debt below 2.0 times adjusted EBITDA, providing financial flexibility to pursue strategic opportunities or weather market downturns. New Frontier Data, a cannabis market research firm, has cited TerrAscend's Pennsylvania market share in published reports analyzing state-level competitive dynamics. According to New Frontier's estimates, TerrAscend holds approximately 12 to 15 percent market share in Pennsylvania by revenue, making it one of the top three operators in the state. This market position provides pricing power and brand recognition that contribute to the strong margins disclosed in earnings reports. Industry observers have noted that TerrAscend's earnings calls provide more detailed operational metrics than many multi-state operator peers, including product category breakdowns, customer acquisition costs, and state-specific performance data. This transparency has been cited as a positive factor for institutional investors conducting due diligence on cannabis sector investments.

What's Next: Future Earnings Catalysts and Decision Points

TerrAscend's future earnings trajectory will be shaped by federal rescheduling decisions, state market maturation, and the company's strategic choices regarding geographic expansion and capital allocation. The most significant near-term catalyst for TerrAscend's earnings is the potential finalization of the DEA's proposed rule to reschedule cannabis to Schedule III. The DEA published a Notice of Proposed Rulemaking in the Federal Register in May 2024, initiating a public comment period and administrative law judge hearing process. If rescheduling is finalized, TerrAscend would immediately benefit from the elimination of 280E tax limitations, potentially increasing net income by $20 million to $30 million annually with no change in operational performance. The timing of a final rule remains uncertain, with estimates ranging from late 2026 to 2027 depending on the outcome of administrative proceedings and potential legal challenges. Pennsylvania's potential move to adult-use cannabis represents a significant growth opportunity for TerrAscend. Legislation to legalize adult-use sales has been introduced in the Pennsylvania General Assembly multiple times but has not advanced to a floor vote. If Pennsylvania legalizes adult-use sales, TerrAscend's existing cultivation capacity and retail footprint would position the company to capture significant market share in what would become one of the largest adult-use markets in the United States. Analysts estimate that Pennsylvania adult-use legalization could increase TerrAscend's annual revenue by $50 million to $100 million within two years of implementation. New Jersey's ongoing license issuance will continue to affect TerrAscend's market share and pricing power in that state. The Cannabis Regulatory Commission has issued hundreds of conditional licenses since 2022, and as these licensees become operational, supply will increase and wholesale pricing will face downward pressure. TerrAscend's earnings reports in 2026 and 2027 will reveal whether the company can maintain market share through brand strength and retail location quality, or whether new entrants erode its position. TerrAscend's management has indicated on recent earnings calls that the company is evaluating strategic alternatives for its California operations, which generate minimal EBITDA. Potential outcomes include the sale of California retail assets, closure of underperforming locations, or a strategic partnership with a California-focused operator. Any decision regarding California will be disclosed in future earnings reports and could improve consolidated margins by eliminating a drag on profitability. The company's balance sheet and capital structure will influence its ability to pursue growth opportunities. TerrAscend's credit facility matures in 2027, and the company will need to refinance this debt or repay it from cash flow. The terms of any refinancing will depend on capital market conditions and lender appetite for cannabis sector exposure. Earnings reports in late 2026 and early 2027 will provide updates on refinancing progress. TerrAscend's next scheduled earnings release is expected in August 2026 for Q2 2026 results, followed by Q3 2026 results in November 2026. These earnings reports will provide updated guidance on full-year 2026 revenue and EBITDA expectations, as well as commentary on the federal rescheduling timeline and state market conditions.

Further Reading and Primary Sources

• TerrAscend Corp. Investor Relations: https://investors.terrascend.com/ — Quarterly earnings releases, financial statements, and earnings call transcripts
• Canadian Securities Exchange Company Profile: https://thecse.com/en/listings/life-sciences/terrascend-corp — Real-time stock data and regulatory filings
• SEDAR+ Database: https://www.sedarplus.ca/ — Official repository for TerrAscend's Canadian securities filings, including annual information forms and MD&A
• U.S. Drug Enforcement Administration Proposed Rescheduling Rule: Federal Register Vol. 89, No. 87 (May 2024) — Full text of proposed rule to reschedule cannabis to Schedule III
• Pennsylvania Department of Health Medical Marijuana Program: https://www.health.pa.gov/topics/programs/Medical%20Marijuana/ — Regulatory framework and licensed operator list
• New Jersey Cannabis Regulatory Commission: https://www.nj.gov/cannabis/ — State regulations, license data, and market statistics
• Michigan Cannabis Regulatory Agency: https://www.michigan.gov/cra — Adult-use market rules and licensee information
• Internal Revenue Code Section 280E: 26 U.S.C. § 280E — Full text of federal tax provision affecting cannabis businesses
• Controlled Substances Act: 21 U.S.C. § 812 — Federal drug scheduling framework
• Viridian Capital Advisors Cannabis Deal Tracker: https://www.viridianca.com/ — Quarterly analysis of multi-state operator financial performance and M&A activity
• New Frontier Data State Market Reports: https://newfrontierdata.com/ — Market sizing and competitive analysis for state-level cannabis markets